Glycogen storage disease

Results: 221



#Item
1How one patient with a rare disease coped with his genetic disorder

How one patient with a rare disease coped with his genetic disorder

Add to Reading List

Source URL: www.epp-deutschland.de

Language: English - Date: 2015-04-23 11:35:57
2LUMIZYME (alglucosidase alfa) for Injection

LUMIZYME (alglucosidase alfa) for Injection

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-05-26 09:39:24
3United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,

United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,

Add to Reading List

Source URL: www.patentchallenges.com

Language: English - Date: 2016-08-09 02:08:12
4Pompe	
  disease	
  (Glycogen	
  storage	
  disease	
  type	
  II) Glycogen	
  storage	
  disease	
  type	
  II	
  is	
  also	
  known	
  as	
  acid	
  maltase	
  deficiency	
  or	
  generalized	
  gl

Pompe  disease  (Glycogen  storage  disease  type  II) Glycogen  storage  disease  type  II  is  also  known  as  acid  maltase  deficiency  or  generalized  gl

Add to Reading List

Source URL: www.finnishlapphund-club.co.uk

Language: English - Date: 2015-06-20 15:57:04
    5Association for Glycogen Storage Disease 2015 Membership Registration Sheet --------------------------------------------------------------------------------------------------------------------------------------------- Pr

    Association for Glycogen Storage Disease 2015 Membership Registration Sheet --------------------------------------------------------------------------------------------------------------------------------------------- Pr

    Add to Reading List

    Source URL: www.agsdus.org

    Language: English - Date: 2015-06-13 12:54:09
      6May 27, 2014  BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

      May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

      Add to Reading List

      Source URL: www.apjohnventures.com

      Language: English - Date: 2014-05-29 15:30:33
      7Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final

      Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final

      Add to Reading List

      Source URL: www.apjohnventures.com

      Language: English
      8Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands  Alexion’s  metabolic  franchise  wi

      Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands  Alexion’s  metabolic  franchise  wi

      Add to Reading List

      Source URL: www.alexion-synagevatransaction.com

      Language: English - Date: 2015-05-06 06:45:36
      9PLEASE TYPE POLICY TITLE HERE

      PLEASE TYPE POLICY TITLE HERE

      Add to Reading List

      Source URL: www.schn.health.nsw.gov.au

      Language: English - Date: 2015-05-30 10:05:51
      10

      PDF Document

      Add to Reading List

      Source URL: www.pbs.gov.au

      Language: English - Date: 2014-10-01 21:56:22